Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 3:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: The Medicines Company Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 2 Interventional Results available

Cangrelor Ticagrelor Transition Study

NCT01766466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
cangrelor, Ticagrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Terminated Phase 4 Interventional

A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)

NCT01033370
View directory record Official record
Conditions
Aortic Aneurysm, Aortic Disease
Interventions
clevidipine.
Drug
Lead sponsor
Asma Zainab, M.D.
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 2 Interventional Results available

Cangrelor to Clopidogrel or Prasugrel Transition Study

NCT01979445
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Cangrelor, Clopidogrel, Prasugrel
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

NCT00666328
View directory record Official record
Conditions
Hypertension, Hemorrhage
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Not applicable Interventional Results available

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NCT02081443
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 180mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

NCT00073593
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Surgery
Interventions
Bivalirudin, Heparin, Protamine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency

NCT02020434
View directory record Official record
Conditions
Subjects With Varying Degrees of Renal Insufficiency and, Subjects With Normal Renal Function
Interventions
RPX7009 and RPX2014
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 8, 2026, 3:43 AM EDT
Withdrawn Phase 4 Interventional

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

NCT01042574
View directory record Official record
Conditions
Hypertension, Intracranial Hemorrhage, Subarachnoid Hemorrhage
Interventions
Clevidipine butyrate
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

NCT02963311
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
ALN-PCSSC, Standard of Care
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

NCT00043940
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Thrombosis
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 2 Interventional Results available

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

NCT00799604
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 4 Interventional Results available

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

NCT02925416
View directory record Official record
Conditions
Skin Diseases, Bacterial
Interventions
Oritavancin, Placebo (D5W)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

NCT02471690
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Dextrose
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571
View directory record Official record
Conditions
Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions
cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
11,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)

NCT00093912
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, sodium nitroprusside
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Montgomery, Alabama • Burbank, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Completed No phase listed Observational

Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

NCT00842374
View directory record Official record
Conditions
Non-STEMI Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waconia, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 8, 2026, 3:43 AM EDT
Withdrawn Phase 4 Interventional

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

NCT00759083
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 8, 2026, 3:43 AM EDT
Withdrawn Phase 3 Interventional

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

NCT04592380
View directory record Official record
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 3 Interventional

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

NCT00369837
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Montgomery, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Terminated Phase 3 Interventional Results available

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138
View directory record Official record
Conditions
Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions
Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
5,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 8, 2026, 3:43 AM EDT
Completed Phase 2 Interventional Results available

Cangrelor Prasugrel Transition Study

NCT01852019
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cangrelor, Prasugrel
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 8, 2026, 3:43 AM EDT
Withdrawn Not applicable Interventional

Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection

NCT01480531
View directory record Official record
Conditions
Aorta Aneurysm, Dissection of Aorta
Interventions
Clevidipine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 8, 2026, 3:43 AM EDT